Trastuzumab in breast cancer metastatic setting: a retrospective study of clinical predictors of exceptional responders
Abstract: Background Currently,human epidermal growth factor 2(HER2)-positive, metastaticbreast cancer is considered an incurable disease;however, a small group can remain in long-term remission with theuse of anti-HER2 treatment. This small group of exceptional responders may beclinicallycured. Aim In this retrospectivecohort study, the aim was to identifythe rate of exceptional respondersto trastuzumab-based therapyand potentialclinical predictive factorsin a consecutive cohortof patients with HER2metastatic breast cancer. Methods Electronic medical records from 148patients with HER2-positive metastatic breast cancer that had received trastuzumab as a first line treatmentwereretrospectively evaluated.The patients included had been treated at three different hospitals in Sweden between 2010-2018. Results In total, 24 patients (16.2%; 95% Confidence Interval (CI): 10.9 –23.4%) were classified as exceptional responders to trastuzumab-based therapy. Two clinical factors were potentially associated to exceptional responses: complete remission as best response in 1st line treatment was associated to higher probability (Odds Ratio (OR): 7.67; 95% CI: 2.63 -22.33);presence of lymph node metastases with lower probability for exceptional response (OR: 0.35; 95% CI: 0.11 -1.09) Conclusion -A meaningful number of patients with HER2-positive metastatic breast cancer are expected to be exceptional responders to trastuzumab-based therapy. The achievementof CRis an important predictive factor for exceptional responses. Additional studies preferably with a uniformand widely accepted definition of exceptional responses are warrantedto confirm our findings and further investigate potential clinical and molecularpredictors.
AT THIS PAGE YOU CAN DOWNLOAD THE WHOLE ESSAY. (follow the link to the next page)